FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
<< Prev  27 28 29 30 31 32 33 34 35 36 37
 
TXT AstraZeneca Scraps Monalizumab Clinical Study
08/01/2022
 
 
TXT FTC Endorsement Guides Require Attention: Lawyer
07/29/2022
 
 
TXT Opioid Questions Continue to Dog Califf: AP
07/28/2022
 
 
TXT Share All Cancer Drug Approval Data: Study
07/28/2022
 
 
TXT 3 Lessons Learned from Fosamax ‘Failure-to-Warn’ Case
07/28/2022
 
 
TXT Micro-Organospheres Show Cancer Proof of Concept: NCI
07/28/2022
 
 
TXT Covidien Recalls Palindrome and Mahurkar Catheters
07/28/2022
 
 
TXT Cassava Sciences Under Criminal Investigation: Reuters
07/27/2022
 
 
TXT FDA OKs Bavarian Nordic’s Vaccine Facility
07/27/2022
 
 
TXT Non-Curative Setting Available Therapy
07/27/2022
 
 
TXT Viz.ai Subdural Hemorrhage Detector Cleared
07/27/2022
 
 
TXT Lexicon Re-files NDA for Heart Failure Drug
07/27/2022
 
 
TXT Cannabis Administration and Opportunity Act
07/27/2022
 
 
TXT ‘Objectionable Conditions’ in Goodman Eye Center Trial
07/27/2022
 
 
TXT CGMP Violations in Bi-Coastal Pharma Inspection
07/26/2022
 
 
TXT API Deviations Found at Jost Chemical
07/26/2022
 
 
TXT Avadel Sues FDA Over Lumryz NDA Delay
07/26/2022
 
 
TXT Develop Regulatory Framework for Synthetic Cells: Paper
07/26/2022
 
 
TXT FDA Accepts Biogen Tofersen NDA for Rare ALS
07/26/2022
 
 
TXT FDA Grants Taiho Oncology Lonsurf Petition
07/26/2022
 
 
TXT Many Supplements Stay on Market After FDA Warning
07/26/2022
 
 
TXT Biotronik Pays $13 Million Under False Claims Case
07/25/2022
 
 
TXT Zipperer Debarred by FDA for 5 Years
07/25/2022
 
 
TXT Draft Guide on Real-time Oncology Reviews
07/25/2022
 
 
TXT Compliance Extension Date on Unique Device IDs
07/22/2022
 
 
TXT FDA Proposes to Move to 12-digit National Drug Codes
07/22/2022
 
 
TXT Regulatory Review Didn’t Slow Covid Vaccines: Marks
07/21/2022
 
 
TXT BioCircuit Technologies 510(k) for Nerve Tape
07/21/2022
 
 
TXT Orange Book Therapeutic Equivalence Guide
07/21/2022
 
 
TXT New Renuvion/J-Plasma Handpiece Available: FDA
07/21/2022
 
 
TXT Whitmer Wants Mifepristone REMS Lifted
07/21/2022
 
 
TXT FDA Refusing to Approve ITCA 650
09/02/2021
 
 
TXT Uproar Greets FDA’s Aduhelm OK for Alzheimer’s
06/08/2021
 
 
TXT CGMP Problems at Catalent Pharma Solutions
04/08/2008
 
 
<< Prev  27 28 29 30 31 32 33 34 35 36 37 
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving